Evidence map›Paper›PMID 33372917›Full record

ArticleRevista espanola de salud publica2020

[Newborn Screening Program in the Community of Madrid: evaluation of positive cases.]

Ana Cambra Conejero, Laura Martínez Figueras, Alicia Ortiz Temprado, Paula Blanco Soto, Álvaro Martín Rivada, Laura Palomino Pérez, Elvira Cañedo Villarroya, Consuelo Pedrón Giner, Pilar Quijada Fraile, Elena Martín-Hernández and 12 more

Open access · greenAbstract read
In one paragraph

Article in Revista espanola de salud publica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Screening for neonatal inherited metabolic disorders by tandem mass spectrometry in Guangzhou.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Ana Cambra ConejeroLaboratorio de Cribado Neonatal de la Comunidad de Madrid. Servicio de Bioquímica Clínica. Hospital General Universitario Gregorio Marañón. Madrid. España.
Laura Martínez FiguerasLaboratorio de Cribado Neonatal de la Comunidad de Madrid. Servicio de Bioquímica Clínica. Hospital General Universitario Gregorio Marañón. Madrid. España.
Alicia Ortiz TempradoLaboratorio de Cribado Neonatal de la Comunidad de Madrid. Servicio de Bioquímica Clínica. Hospital General Universitario Gregorio Marañón. Madrid. España.
Paula Blanco SotoLaboratorio de Cribado Neonatal de la Comunidad de Madrid. Servicio de Bioquímica Clínica. Hospital General Universitario Gregorio Marañón. Madrid. España.
Álvaro Martín RivadaSección de Gastroenterología y Nutrición. Hospital Infantil Universitario Niño Jesús. Madrid. España.
Laura Palomino PérezSección de Gastroenterología y Nutrición. Hospital Infantil Universitario Niño Jesús. Madrid. España.
Elvira Cañedo VillarroyaSección de Gastroenterología y Nutrición. Hospital Infantil Universitario Niño Jesús. Madrid. España.
Consuelo Pedrón GinerSección de Gastroenterología y Nutrición. Hospital Infantil Universitario Niño Jesús. Madrid. España.
Pilar Quijada FraileUnidad de Enfermedades Mitocondriales-Metabólicas Hereditarias. Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) en Enfermedades Metabólicas. Hospital Universitario 12 de Octubre. Madrid. España.
Elena Martín-HernándezUnidad de Enfermedades Mitocondriales-Metabólicas Hereditarias. Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) en Enfermedades Metabólicas. Hospital Universitario 12 de Octubre. Madrid. España.
María Teresa García SilvaUnidad de Enfermedades Mitocondriales-Metabólicas Hereditarias. Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) en Enfermedades Metabólicas. Hospital Universitario 12 de Octubre. Madrid. España.
Silvia Chumillas CalzadaUnidad de Enfermedades Mitocondriales-Metabólicas Hereditarias. Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) en Enfermedades Metabólicas. Hospital Universitario 12 de Octubre. Madrid. España.
Marcello BellusciUnidad de Enfermedades Mitocondriales-Metabólicas Hereditarias. Centro de Referencia Nacional (CSUR) y Europeo (MetabERN) en Enfermedades Metabólicas. Hospital Universitario 12 de Octubre. Madrid. España.
Amaya Belanger-QuintanaCentro de Referencia Nacional (CSUR) en Enfermedades Metabólicas. Hospital Universitario Ramón y Cajal. Madrid. España.
Sinziana StanescuCentro de Referencia Nacional (CSUR) en Enfermedades Metabólicas. Hospital Universitario Ramón y Cajal. Madrid. España.
Mercedes Martínez-Pardo CasanovaCentro de Referencia Nacional (CSUR) en Enfermedades Metabólicas. Hospital Universitario Ramón y Cajal. Madrid. España.
Ana Moráis LópezUnidad de Nutrición Infantil y Enfermedades Metabólicas. Hospital Universitario La Paz. Madrid. España.
Ana Bergua MartínezUnidad de Nutrición Infantil y Enfermedades Metabólicas. Hospital Universitario La Paz. Madrid. España.
Pedro Ruiz-SalasCentro de Diagnóstico de Enfermedades Moleculares. Universidad Autónoma de Madrid. IdiPAZ. CIBERER. Madrid. España.
Belén Pérez GonzálezCentro de Diagnóstico de Enfermedades Moleculares. Universidad Autónoma de Madrid. IdiPAZ. CIBERER. Madrid. España.
Magdalena UgarteCentro de Diagnóstico de Enfermedades Moleculares. Universidad Autónoma de Madrid. IdiPAZ. CIBERER. Madrid. España.
Miguel L F RuanoLaboratorio de Cribado Neonatal de la Comunidad de Madrid. Servicio de Bioquímica Clínica. Hospital General Universitario Gregorio Marañón. Madrid. España.
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESHospital General Universitario Gregorio Marañón · ESHospital Infantil Universitario Niño Jesús · ESHospital Universitario Ramón y Cajal · ESUniversidad Autónoma de Madrid · ESHospital Universitario La Paz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTandem mass spectrometry (MS/MS) is being used for newborn screening since this laboratory testing technology increases the number of metabolic disorders that can be detected from dried blood-spot specimens. In the Community of Madrid, it was implemented in March 2011 and it includes 13 aminoacidopathies, fatty acid oxidation disorders and organic acidemias. The aim of this study was to describe our experience and evaluate the screening positive cases in a period of 9 years (2011-2019).

methodsDuring the period of the study, a total of 592.822 neonates were screened with this expanded program by MS/MS in the Community of Madrid. Amino acids, acylcarnitines, and succinylacetone were quantified in all samples that met the quality criteria. Means, medians, percentiles and standard deviation of the analytes and ratios of interest were calculated.

results901 patients (0,15 %) with a positive screening test were referred to clinical evaluation. 230 patients were diagnosed of 30 different inborn errors of metabolism (prevalence 1:2577), 11 of which were not included as a target in the Community of Madrid newborn screening program. The global positive predictive value was 25,6 %. During this period of time, two false negative cases were detected. The most prevalent disorders were phenylketonuria/hyperphenylalaninemia and medium chain acyl-CoA dehydrogenase deficiency (1:6444 and 1:13174 respectively). 93 % of the patients were detected in the presymptomatic stage.

conclusionsDuring the last 9 years a large number of cases of IEM have been detected with an acceptable global positive predictive value. These results confirm the utility of inborn errors of metabolism newborn screening as a public health program.

Indexed as

Acyl-CoA DehydrogenaseAmino Acid Metabolism, Inborn ErrorsCarnitineCitiesFemaleHumansInfant, NewbornLipid Metabolism, Inborn ErrorsMaleNeonatal ScreeningPredictive Value of TestsPrevalenceSpainTandem Mass SpectrometryacylcarnitineAcyl-CoA DehydrogenaseCarnitineExpanded newborn screeningFalse positiveInborn errors of metabolismSpainTandem mass spectrometry

Identifiers

PMID33372917
PMCPMC11582918
OpenAlexW3117559877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.